Prab: CSV import

2025-02-17T01:52:56Z

CSV import

← Older revision		Revision as of 01:52, 17 February 2025
Line 18:		Line 18:

	{{coststubd}}		{{coststubd}}
			<gallery>
			File:Disopyramide.svg\|Disopyramide chemical structure
			File:Disopramide.png\|Disopyramide packaging
			</gallery>

Prab at 18:02, 25 April 2019

2019-04-25T18:02:40Z

New page

{{intro}}
Disopyramide is an oral antiarrhythmic agent that has been in wide use for several decades.

{{livtox}}
Long term disopyramide therapy is associated with a low rate of serum enzyme elevations and is a rare cause of clinically apparent acute [[liver injury]].

{{moa}}
Disopyramide (dye" soe pir' a mide) is a pyridine derivative and has electrophysiological effects that resemble quinidine (antiarrhythmic Class IA). Disopyramide decreases cardiac automaticity, increases refractory periods and slows conduction. Disopyramide is considered a myocardial depressant and can depress contractility. It also has anticholinergic effects. Disopyramide was approved for use in the United States in 1977, and current indications include suppression of symptomatic premature ventricular contractions and life threatening ventricular [[tachycardia]]. It is also effective in conversion as well as maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter, but is not approved for this indication in the United States.

{{dose}
Disopyramide is available in capsules of 100 and 150 mg generically and under the brand name Norpace. Extended release formulations are also available. The usual maintenance dose in adults is 400 to 800 mg daily in 2 to 4 divided doses.

{{se}}
The most common side effects include [[dry mouth]], urinary hesitancy, [[fatigue]], [[headache]], [[dizziness]] and [[anxiety]].

{{antiarrhythmic agents}}

{{coststubd}}

Disopyramide - Revision history

Prab: CSV import

Prab at 18:02, 25 April 2019